Cargando…

Identification, Evaluation, and Treatment of Patients with Hereditary Cancer Risk within the United States

Recognizing the importance of identifying patients at high risk for inherited cancer predisposition, the United States Preventive Services Task Force (USPSTF) has outlined specific family history patterns associated with an increased risk for BRCA mutations. However, national data indicate a need to...

Descripción completa

Detalles Bibliográficos
Autores principales: Cragun, Deborah, Pal, Tuya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3884954/
https://www.ncbi.nlm.nih.gov/pubmed/24455306
http://dx.doi.org/10.1155/2013/260847
_version_ 1782298677550776320
author Cragun, Deborah
Pal, Tuya
author_facet Cragun, Deborah
Pal, Tuya
author_sort Cragun, Deborah
collection PubMed
description Recognizing the importance of identifying patients at high risk for inherited cancer predisposition, the United States Preventive Services Task Force (USPSTF) has outlined specific family history patterns associated with an increased risk for BRCA mutations. However, national data indicate a need to facilitate the ability of primary care providers to appropriately identify high risk patients. Once a patient is identified as high risk, it is necessary for the patient to undergo a detailed genetics evaluation to generate a differential diagnosis, determine a cost-effective genetic testing strategy, and interpret results of testing. With identification of inherited predisposition, risk management strategies in line with national guidelines can be implemented to improve patient outcomes through cancer risk reduction and early detection. As use of genetic testing increasingly impacts patient outcomes, the role of primary care providers in the identification and care of individuals at high risk for hereditary cancer becomes even more important. Nevertheless it should be acknowledged that primary care providers face many competing demands and challenges to identify high risk patients. Therefore initiatives which promote multidisciplinary and coordinated care, potentially through academic-community partnerships, may provide an opportunity to enhance care of these patients.
format Online
Article
Text
id pubmed-3884954
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-38849542014-01-21 Identification, Evaluation, and Treatment of Patients with Hereditary Cancer Risk within the United States Cragun, Deborah Pal, Tuya ISRN Oncol Review Article Recognizing the importance of identifying patients at high risk for inherited cancer predisposition, the United States Preventive Services Task Force (USPSTF) has outlined specific family history patterns associated with an increased risk for BRCA mutations. However, national data indicate a need to facilitate the ability of primary care providers to appropriately identify high risk patients. Once a patient is identified as high risk, it is necessary for the patient to undergo a detailed genetics evaluation to generate a differential diagnosis, determine a cost-effective genetic testing strategy, and interpret results of testing. With identification of inherited predisposition, risk management strategies in line with national guidelines can be implemented to improve patient outcomes through cancer risk reduction and early detection. As use of genetic testing increasingly impacts patient outcomes, the role of primary care providers in the identification and care of individuals at high risk for hereditary cancer becomes even more important. Nevertheless it should be acknowledged that primary care providers face many competing demands and challenges to identify high risk patients. Therefore initiatives which promote multidisciplinary and coordinated care, potentially through academic-community partnerships, may provide an opportunity to enhance care of these patients. Hindawi Publishing Corporation 2013-12-22 /pmc/articles/PMC3884954/ /pubmed/24455306 http://dx.doi.org/10.1155/2013/260847 Text en Copyright © 2013 D. Cragun and T. Pal. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Cragun, Deborah
Pal, Tuya
Identification, Evaluation, and Treatment of Patients with Hereditary Cancer Risk within the United States
title Identification, Evaluation, and Treatment of Patients with Hereditary Cancer Risk within the United States
title_full Identification, Evaluation, and Treatment of Patients with Hereditary Cancer Risk within the United States
title_fullStr Identification, Evaluation, and Treatment of Patients with Hereditary Cancer Risk within the United States
title_full_unstemmed Identification, Evaluation, and Treatment of Patients with Hereditary Cancer Risk within the United States
title_short Identification, Evaluation, and Treatment of Patients with Hereditary Cancer Risk within the United States
title_sort identification, evaluation, and treatment of patients with hereditary cancer risk within the united states
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3884954/
https://www.ncbi.nlm.nih.gov/pubmed/24455306
http://dx.doi.org/10.1155/2013/260847
work_keys_str_mv AT cragundeborah identificationevaluationandtreatmentofpatientswithhereditarycancerriskwithintheunitedstates
AT paltuya identificationevaluationandtreatmentofpatientswithhereditarycancerriskwithintheunitedstates